"text","description","id","label","name","instanceType","uuid:ID"
"To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%","","Objective_1","","OBJ1","Objective","5613e75f-9efb-488a-bc0e-63a17c8774ba"
"To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG","","Objective_2","","OBJ2","Objective","f43eb9dd-3a7f-40b5-8b8d-dae12fb388c6"
"To characterize the PK profile of 3 mg LY900018
compared to 1 mg IMG","","Objective_3","","OBJ3","Objective","2e463d50-51c8-471e-a424-c49dd0533049"
"To characterize the PD profile of 3 mg LY900018
compared to 1 mg IMG","","Objective_4","","OBJ4","Objective","c196c902-e6bb-4498-8f5d-13b23a40cb75"
"Explore the formation of anti-glucagon antibodies to glucagon","","Objective_5","","OBJ5","Objective","3da8e810-964a-47f2-95cd-5da651cad034"
"To evaluate the recovery from clinical symptoms of hypoglycemia","","Objective_6","","OBJ6","Objective","daa66081-b01d-432f-a2ad-35428d3dbd1d"
